Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients - ACR Meeting Abstracts

Abstract Number: 1484

Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients

Megan Zhao¹, Kevin Williams², Douglas Jacoby³, Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, Philadelphia, ²Temple University Hospital System, Philadelphia, ³University of Pennsylvania Health System, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia

Meeting: ACR Convergence 2022

Keywords: Cardiovascular, Cohort Study, Heart disease, lupus-like disease, risk factors

Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Lupus erythematosus (LE) patients are at heightened risk of clinical events, chiefly heart attacks and strokes, caused by ASCVD. To address this problem, we recently proposed new guidelines forcategorization of levels of risk for ASCVD events in LE patients, with corresponding recommendations for management of conventional risk factors, chiefly hypercholesterolemia, hypertension, smoking, and diabetes mellitus (Keyes E et al. 2021).

Methods: Here, we performed a single-center study of our established cohort of cutaneous LE patients without or with concurrent systemic LE (n=370). Our goal was to assess how current management compares with the newly proposed guidelines.

Results: Of our LE cohort, 336/370 (90.8%) had a designated primary care physician. By the newly proposed guidelines, the most recent plasma low-density lipoprotein cholesterol (LDLc) levels for 254/370 (68.6%) of the LE cohort were above goal. Of those 254 LE patients with above-goal LDLc, the following were not on any LDL-lowering medications: 13/15 (86.7%) classified at high ASCVD event risk, 121/177 (68.4%) at very high event risk, and 24/62 (38.7%) at extreme ASCVD event risk. The American College of Cardiology calculator for the 10-year risk of an ASCVD event could be used on 248/370 (67.0%) of the LE cohort. Of those 248 LE patients, the following were not on LDL-lowering medications: 109/129 (84.5%) who had a calculated 10-year event risk < 5%, 34/49 (69.4%) with 5-< 10% risk, 23/43 (53.5%) with 10-< 20% risk, and 11/27 (40.7%) with ≥20% risk. Of LE patients with clinically evident ASCVD, 36/82 (43.9%) were not on LDL-lowering medications.

Conclusion: We conclude that LE patients are undertreated for conventional ASCVD risk factors. Efforts to improve the problem are underway.

Table 1. Demographics and other characteristics of the LE-ASCVD Study cohort.
Categorical parameter¬s are given as n (%). Continuous variables are given as mean±SD if normally distributed, or as median (interquartile range, IQR) if non-normally distributed.

Assessment and management of plasma low-density lipoprotein cholesterol (LDLc) concentrations in the LE-ASCVD Study cohort. Panel A: ASCVD event risk categories by the newly proposed guidelines for lupus patients (Keyes et al. 2021) and achievement (green), or not (red), of the newly proposed LDLc goals for each risk category. Patients without an available LDLc value are indicated in blue.

Assessment and management of plasma low-density lipoprotein cholesterol (LDLc) concentrations in the LE-ASCVD Study cohort. Panel B: LDL-lowering medication use (green), or not (red), in patients assigned to each newly proposed risk category for lupus patients (Keyes et al. 2021) whose most recent plasma LDLc levels were above the newly proposed goals; these are the patients indicated in red in panel A.

Disclosures: M. Zhao, None; K. Williams, None; D. Jacoby, None; R. Feng, None; V. Werth, GlaxoSmithKline, CLASI.

To cite this abstract in AMA style:

Zhao M, Williams K, Jacoby D, Feng R, Werth V. Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/management-of-the-heightened-risk-for-clinical-events-from-atherosclerotic-cardiovascular-disease-ascvd-in-an-established-cohort-of-lupus-erythematosus-patients/. Accessed .

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/management-of-the-heightened-risk-for-clinical-events-from-atherosclerotic-cardiovascular-disease-ascvd-in-an-established-cohort-of-lupus-erythematosus-patients/

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].